Relay Therapeutics, Inc. (RLAY) stock
RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$15.91−0.60 (-3.63%)
Close on Nov 19, 2026Market cap $3.49BP/E –Yield –
Relay Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Relay Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$235.87M. For fiscal 2025 it was -$235.87M. The highest annual figure on record is -$74.14M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$235.87M | – |
| FY2024 | Dec 31, 2024 | -$251.13M | – |
| FY2023 | Dec 31, 2023 | -$304.44M | – |
| FY2022 | Dec 31, 2022 | -$238.55M | – |
| FY2021 | Dec 31, 2021 | -$77.88M | – |
| FY2020 | Dec 31, 2020 | -$104.42M | – |
| FY2019 | Dec 31, 2019 | -$74.14M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$44.87M | – |
| Q3 FY2025 | Sep 30, 2025 | -$62.12M | – |
| Q2 FY2025 | Jun 30, 2025 | -$55.29M | – |
| Q1 FY2025 | Mar 31, 2025 | -$73.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$57.87M | – |
| Q3 FY2024 | Sep 30, 2024 | -$75.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$65.84M | – |
| Q1 FY2024 | Mar 31, 2024 | -$52.10M | – |
| Q4 FY2023 | Dec 31, 2023 | -$89.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$75.99M | – |
| Q2 FY2023 | Jun 30, 2023 | -$70.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$69.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$59.40M | – |
| Q3 FY2022 | Sep 30, 2022 | -$68.24M | – |
| Q2 FY2022 | Jun 30, 2022 | -$58.95M | – |
| Q1 FY2022 | Mar 31, 2022 | -$51.97M | -212.6% |
| Q4 FY2021 | Dec 31, 2021 | -$40.59M | – |
| Q3 FY2021 | Sep 30, 2021 | -$54.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$28.52M | – |
| Q1 FY2021 | Mar 31, 2021 | $46.16M | – |
| Q4 FY2020 | Dec 31, 2020 | -$35.34M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.47M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.26M | – |
| Q1 FY2020 | Mar 31, 2020 | -$23.35M | – |
| Q4 FY2019 | Dec 31, 2019 | -$23.36M | – |
| Q3 FY2019 | Sep 30, 2019 | -$19.89M | – |
See a number that looks wrong?